Related Experiment Videos
Lymphangiogenesis in tumors: what do we know?
Jorge Sergio Reis-Filho1, Fernando C Schmitt
1Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, S/N 4200 Porto, Portugal.
Microscopy Research and Technique
|January 23, 2003
Summary
Lymphangiogenesis, the growth of new lymphatic vessels, is a key pathway for cancer spread. Recent advances in lymphatic endothelial cell (LEC) markers and the VEGF-C/VEGFR-3 pathway have clarified its role in neoplasms.
Area of Science:
- Oncology
- Vascular Biology
- Pathology
Background:
- Lymphangiogenesis, the formation of new lymphatic vessels, has been implicated in cancer metastasis.
- Historically, a lack of reliable lymphatic endothelial cell (LEC) markers and definitive evidence hindered understanding.
- The role of newly formed lymphatic vessels in tumors was a debated topic.
Purpose of the Study:
- To review significant advancements in the field of lymphangiogenesis.
- To highlight novel and reliable LEC markers.
- To discuss the pathological assessment of lymphangiogenesis as a prognostic factor in human neoplasms.
Main Methods:
- Literature review of recent breakthroughs in lymphangiogenesis research.
- Focus on novel LEC markers including prox-1, LYVE-1, and podoplanin.
- Examination of the VEGF-C/VEGFR-3 pathway's role.
Main Results:
- Consistent reports now describe novel LEC markers, validating their utility.
- The presence of new lymphatic vessels in tumors is now demonstrable in animal models and human neoplasms.
- The VEGF-C/VEGFR-3 pathway has been characterized, providing mechanistic insights.
Conclusions:
- Recent scientific progress has significantly clarified the role of lymphangiogenesis in cancer.
- Novel LEC markers and pathway characterization offer improved diagnostic and prognostic potential.
- Pathological assessment of lymphangiogenesis is crucial for evaluating prognosis in human neoplasms.